Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 101
Filtrer
1.
NPJ Syst Biol Appl ; 10(1): 23, 2024 Mar 02.
Article de Anglais | MEDLINE | ID: mdl-38431714

RÉSUMÉ

Skin cancer and other skin-related inflammatory pathologies are rising due to heightened exposure to environmental pollutants and carcinogens. In this context, natural products and repurposed compounds hold promise as novel therapeutic and preventive agents. Strengthening the skin's antioxidant defense mechanisms is pivotal in neutralizing reactive oxygen species (ROS) and mitigating oxidative stress. Sunset Yellow (SY) exhibits immunomodulatory characteristics, evidenced by its capacity to partially inhibit the secretion of proinflammatory cytokines, regulate immune cell populations, and modulate the activation of lymphocytes. This study aimed to investigate the antioxidant and anti-genotoxic properties of SY using in-silico, in vitro, and physiochemical test systems, and to further explore its potential role in 7,12-dimethylbenz(a) anthracene (DMBA)/ 12-o-tetradecanoylphorbol-13-acetate (TPA)-induced two-stage skin carcinogenesis. In vitro experiments showed that pre-treatment of SY significantly enhanced the cell viability of HaCaT cells when exposed to tertiary-Butyl Hydrogen Peroxide (tBHP). This increase was accompanied by reduced ROS levels, restoration of mitochondrial membrane potential, and notable reduction in DNA damage in (SY + tBHP) treated cells. Mechanistic investigations using DPPH chemical antioxidant activity test and potentiometric titrations confirmed SY's antioxidant properties, with a standard reduction potential ( E o ) of 0.211 V. Remarkably, evaluating the effect of topical application of SY in DMBA/TPA-induced two-step skin carcinogenesis model revealed dose-dependent decreases in tumor latency, incidence, yield, and burden over 21-weeks. Furthermore, computational analysis and experimental validations identified GSK3ß, KEAP1 and EGFR as putative molecular targets of SY. Collectively, our findings reveal that SY enhances cellular antioxidant defenses, exhibits anti-genotoxic effects, and functions as a promising chemopreventive agent.


Sujet(s)
Antioxydants , Composés azoïques , Tumeurs cutanées , Humains , Protéine-1 de type kelch associée à ECH/métabolisme , Antioxydants/effets indésirables , Antioxydants/métabolisme , Espèces réactives de l'oxygène/métabolisme , Facteur-2 apparenté à NF-E2/métabolisme , Facteur-2 apparenté à NF-E2/usage thérapeutique , 7,12-Diméthyl-benzo[a]anthracène/toxicité , Tumeurs cutanées/induit chimiquement , Tumeurs cutanées/traitement médicamenteux , Tumeurs cutanées/prévention et contrôle , 12-Myristate-13-acétate de phorbol/effets indésirables , Stress oxydatif , Chimioprévention , Carcinogenèse
2.
Article de Anglais | MEDLINE | ID: mdl-36515033

RÉSUMÉ

BACKGROUND: In traditional medicine, Linum usitatissimum treats inflammatory, gastrointestinal, and cardiovascular diseases. OBJECTIVES: The present study aims to assess the anti-inflammatory and anti-oxidant effects of total alkaloid extract from Linum usitatissimum seeds (ALU) on the ear histological integrity and oxidant- antioxidant status in a mice model of a sub-chronic inflammation induced by multiapplication of TPA. METHODS: Topical TPA treatment induced various inflammatory changes, including edema formation, epidermal thickness, and the excess production of reactive oxygen species. Tissue samples were used for the measurement of reduced glutathione (GSH) and nitric oxide (NO) levels and Myeloperoxidase (MPO) and Catalase (CAT) activities. RESULTS: Oral administration of ALU (50, 100, and 200 mg/kg) produced anti-inflammatory and anti-oxidant effects. Also, ALU significantly reduced ear edema and inflammatory cell infiltration and restored the integrity of the ear. CONCLUSION: These findings suggest that the total alkaloid extract from Linum usitatissimum seeds presents significant anti-inflammatory and anti-oxidant effects on TPA-induced sub-chronic inflammation model in NMRI mice and can be used as an anti-inflammatory and anti-oxidant agent for the therapeutic management of inflammatory disorders.


Sujet(s)
Alcaloïdes , Lin , Souris , Animaux , Antioxydants/pharmacologie , Antioxydants/usage thérapeutique , Inflammation/induit chimiquement , Inflammation/traitement médicamenteux , Anti-inflammatoires/pharmacologie , Anti-inflammatoires/usage thérapeutique , Stress oxydatif , Extraits de plantes/pharmacologie , Extraits de plantes/usage thérapeutique , Alcaloïdes/pharmacologie , Alcaloïdes/usage thérapeutique , Acétates/usage thérapeutique , Oedème/induit chimiquement , Oedème/traitement médicamenteux , 12-Myristate-13-acétate de phorbol/effets indésirables
3.
Methods Cell Biol ; 171: 63-80, 2022.
Article de Anglais | MEDLINE | ID: mdl-35953206

RÉSUMÉ

Skin squamous cell carcinoma (skin SCC) is the most frequently occurring cancer. Skin is the first line of defense that provides protection from the external environment. Skin consists of epidermis, dermis, and hypodermis. The epidermis comprises of inter-follicular epidermis, hair follicles, sebaceous glands, and sweat glands. Stem cells within these epidermal compartments play crucial role in epidermal regeneration and repair. Various factors such as higher exposure to ultraviolet light (UV) of sun, genetic predisposition, exposure to carcinogens, etc. that give rise to skin cancer. Within the skin SCC, there exists a pool of cancer stem cells (CSCs) that are highly quiescent with self-renewal capacity. Further, isolation and molecular characterization of CSCs would enable to unravel mechanism involved in tumor progression, metastasis, relapse, and resistance to chemotherapeutic agents. To understand the sequential events of carcinogenesis, the two-stage skin carcinogenesis murine model is proposed, which employs the topical application of a chemical carcinogen, DMBA that causes several activating mutations occurring in the genes responsible for cell proliferation and growth. Further, initiation is followed by tumor promotion, which is induced by repeated application of tumor-promoting agent, TPA, which fixes the activating mutations resulting in the formation of a benign papilloma. Subsequently, papilloma further progresses to highly malignant SCC. Here, using the two-stage skin carcinogenesis murine model, we provide a detailed protocol for the isolation of CSCs from murine skin SCC. FACS sorting of CSCs is followed by assays such as invitro-spheroid assay, in vivo-tumorigenesis-limiting dilution and in vivo-tumorigenesis-serial transplantation assay and expression profiling.


Sujet(s)
Carcinome épidermoïde , Papillome , Tumeurs cutanées , 7,12-Diméthyl-benzo[a]anthracène/effets indésirables , Animaux , Carcinogenèse , Cancérogènes , Carcinome épidermoïde/induit chimiquement , Carcinome épidermoïde/complications , Carcinome épidermoïde/génétique , Modèles animaux de maladie humaine , Humains , Souris , Cellules souches tumorales/anatomopathologie , Papillome/induit chimiquement , Papillome/anatomopathologie , Tumeurs cutanées/induit chimiquement , Tumeurs cutanées/génétique , 12-Myristate-13-acétate de phorbol/effets indésirables
4.
Theranostics ; 12(6): 2613-2630, 2022.
Article de Anglais | MEDLINE | ID: mdl-35401828

RÉSUMÉ

Background: Insulin-like growth factor 1 receptor (IGF-1R) expression and signaling play important roles in promotion of skin cancer progression. Identification of signaling pathways that regulate IGF-1R is crucial for understanding the pathogenesis and therapeutic treatment of skin cancer. Methods: Molecular, cellular and genetic approaches were used to investigate the function of PINCH-1 in regulation of IGF-1R expression and skin cell behavior. Furthermore, conditional PINCH-1 knockout mouse and carcinogen (7, 12-dimethylbenz[a]anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA))-induced skin cancer model were employed to determine the function of PINCH-1 in regulation of IGF-1R expression and skin carcinogenesis in vivo. Results: Knockdown of PINCH-1 from HaCaT keratinocytes or A431 squamous carcinoma cells diminished IGF-1R levels, suppressed cell proliferation and increased apoptosis. Re-expression of PINCH-1 in PINCH-1 knockdown cells restored IGF-1R expression, cell proliferation and survival. Furthermore, depletion of NEDD4 effectively reversed PINCH-1 deficiency-induced down-regulation of IGF-1R expression, cell proliferation and survival. Conditional knockout of PINCH-1 from keratin 5 (K5) positive keratinocytes in mice, like depletion of PINCH-1 from keratinocytes in culture, reduced the IGF-1R level. Using a mouse model of DMBA/TPA-induced skin cancer, we show that the levels of both PINCH-1 and IGF-1R were significantly increased in response to treatment with the carcinogens. Genetic ablation of PINCH-1 from the epidermis markedly reduced the IGF-1R expression and cell proliferation despite stimulation with DMBA/TPA, resulting in resistance to chemical carcinogen-induced skin cancer initiation and progression. Conclusions: Our results reveal a PINCH-1-NEDD4-IGF-1R signaling axis that is critical for promotion of skin tumorigenesis and suggest a new strategy for therapeutic control of skin cancer progression.


Sujet(s)
Récepteur IGF de type 1 , Tumeurs cutanées , Animaux , Carcinogenèse/anatomopathologie , Cancérogènes/métabolisme , Prolifération cellulaire , Protéine adaptatrice GRB10/métabolisme , Protéine adaptatrice GRB10/pharmacologie , Kératinocytes , Souris , Récepteur IGF de type 1/génétique , Peau/anatomopathologie , Tumeurs cutanées/induit chimiquement , Tumeurs cutanées/génétique , Tumeurs cutanées/métabolisme , 12-Myristate-13-acétate de phorbol/effets indésirables , 12-Myristate-13-acétate de phorbol/métabolisme
5.
Molecules ; 27(2)2022 Jan 13.
Article de Anglais | MEDLINE | ID: mdl-35056807

RÉSUMÉ

Cannabigerol (CBG) is a minor non-psychoactive cannabinoid present in Cannabis sativa L. (C. sativa) at low levels (<1% per dry weight) that serves as the direct precursor to both cannabidiol (CBD) and tetrahydrocannabinol (THC). Consequently, efforts to extract and purify CBG from C. sativa is both challenging and expensive. However, utilizing a novel yeast fermentation technology platform, minor cannabinoids such as CBG can be produced in a more sustainable, cost-effective, and timely process as compared to plant-based production. While CBD has been studied extensively, demonstrating several beneficial skin properties, there are a paucity of studies characterizing the activity of CBG in human skin. Therefore, our aim was to characterize and compare the in vitro activity profile of non-psychoactive CBG and CBD in skin and be the first group to test CBG clinically on human skin. Gene microarray analysis conducted using 3D human skin equivalents demonstrates that CBG regulates more genes than CBD, including several key skin targets. Human dermal fibroblasts (HDFs) and normal human epidermal keratinocytes (NHEKs) were exposed in culture to pro-inflammatory inducers to trigger cytokine production and oxidative stress. Results demonstrate that CBG and CBD reduce reactive oxygen species levels in HDFs better than vitamin C. Moreover, CBG inhibits pro-inflammatory cytokine (Interleukin-1ß, -6, -8, tumor necrosis factor α) release from several inflammatory inducers, such as ultraviolet A (UVA), ultraviolet B (UVB), chemical, C. acnes, and in several instances does so more potently than CBD. A 20-subject vehicle-controlled clinical study was performed with 0.1% CBG serum and placebo applied topically for 2 weeks after sodium lauryl sulfate (SLS)-induced irritation. CBG serum showed statistically significant improvement above placebo for transepidermal water loss (TEWL) and reduction in the appearance of redness. Altogether, CBG's broad range of in vitro and clinical skin health-promoting activities demonstrates its strong potential as a safe, effective ingredient for topical use and suggests there are areas where it may be more effective than CBD.


Sujet(s)
Anti-inflammatoires/pharmacologie , Cannabinoïdes/biosynthèse , Cannabinoïdes/pharmacologie , Produits dermatologiques/pharmacologie , Saccharomyces cerevisiae/génétique , Anti-inflammatoires/usage thérapeutique , Antioxydants/pharmacologie , Antioxydants/usage thérapeutique , Cannabidiol/pharmacologie , Cannabinoïdes/usage thérapeutique , Cellules cultivées , Eczéma de contact/traitement médicamenteux , Eczéma de contact/étiologie , Produits dermatologiques/usage thérapeutique , Femelle , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Volontaires sains , Humains , Inflammation/étiologie , Inflammation/prévention et contrôle , Mâle , Modèles biologiques , Propionibacteriaceae , Peau/effets des médicaments et des substances chimiques , Vieillissement de la peau/effets des médicaments et des substances chimiques , Tests d'irritation cutanée , Dodécyl-sulfate de sodium/toxicité , 12-Myristate-13-acétate de phorbol/effets indésirables , Analyse sur puce à tissus , Rayons ultraviolets/effets indésirables
6.
Dermatitis ; 33(4): 277-281, 2022.
Article de Anglais | MEDLINE | ID: mdl-33654018

RÉSUMÉ

BACKGROUND: Chronic inflammatory skin disorders, such as atopic dermatitis, have significant disease burden worldwide. Although efficacious, the adverse effect profile of topical corticosteroids limits long-term use. As an alternative, cannabinoids have been shown to have anti-inflammatory therapeutic effects. OBJECTIVE: The aim of this study was to assess the effects of a topical cannabinoid product using dermatitis mouse model. METHODS: Thirty-five mice were randomized into treatment groups. 12- O -tetradecanoylphorbol-13-acetate was used as an irritant on 1 ear with the contralateral ear serving as a control. Ear edema was calipered. The test product containing 0.9% cannabidiol and palmitoylethanolamide was compared with a potent topical corticosteroid. RESULTS: Treatment with topical cannabinoid formulation reduced ear edema by 51.27% at 24 hours' and 65.69% at 48 hours' postapplication. Alternatively, mometasone reduced ear edema by 89.82% at 24 hours and 98.25% at 48 hours. Natural reduction (control) in ear edema was 26.32% at 24 hours and 44.21% at 48 hours. Both test groups resulted in significantly decreased edema when compared with baseline ( P < 0.05), as well as compared with the negative control group ( P < 0.05). CONCLUSIONS: Significant reduction in ear edema, a marker for localized cutaneous inflammation, could be attributed to anti-inflammatory properties of cannabinoids. Although effects were less robust than topical corticosteroid use, cannabinoid formulations have therapeutic promise for dermatitis.


Sujet(s)
Cannabidiol , Dermatite , Acétates/effets indésirables , Amides , Animaux , Anti-inflammatoires/effets indésirables , Cannabidiol/effets indésirables , Dermatite/traitement médicamenteux , Oedème/induit chimiquement , Oedème/traitement médicamenteux , Éthanolamines , Souris , Acides palmitiques , 12-Myristate-13-acétate de phorbol/effets indésirables
7.
Int J Mol Sci ; 21(23)2020 Dec 04.
Article de Anglais | MEDLINE | ID: mdl-33291656

RÉSUMÉ

Phorbol 12-myristate 13-acetate (PMA) is a potent tumor promoter and highly inflammatory in nature. Here, we investigated the toxic effects of PMA on different model system. PMA (10 µg) caused chromosomal aberrations on the Allium cepa root tip and induced mitotic dysfunction. Similarly, PMA caused embryonic and larval deformities and a plummeted survivability rate on zebrafish embryo in a dose-dependent manner. Persistently, PMA treatment on immortalized human keratinocyte human keratinocyte (HaCaT) cells caused massive inflammatory rush at 4 h and a drop in cell survivability at 24 h. Concomitantly, we replicated a cutaneous inflammation similar to human psoriasis induced by PMA. Herein, we used tangeretin (TAN), as an antagonist to counteract the inflammatory response. Results from an in vivo experiment indicated that TAN (10 and 30 mg/kg) significantly inhibited PMA stimulated epidermal hyperplasia and intra-epidermal neutrophilic abscesses. In addition, its treatment effectively neutralized PMA induced elevated reactive oxygen species (ROS) generation on in vitro and in vivo systems, promoting antioxidant response. The association of hypoxia-inducible factor 1-alpha (HIF-1α)-nuclear factor kappa-light-chain-enhancer of activated b cells (NF-κB) crosstalk triggered by PMA enhanced PKCα-ERK1/2-NF-κB pathway; its activation was also significantly counteracted after TAN treatment. Conclusively, we demonstrated TAN inhibited the nuclear translocation of HIF-1α and NF-κB p65. Collectively, TAN treatment ameliorated PMA incited malignant inflammatory response by remodeling the cutaneous microenvironment.


Sujet(s)
Flavones/pharmacologie , Sous-unité alpha du facteur-1 induit par l'hypoxie/métabolisme , Facteur de transcription NF-kappa B/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , 12-Myristate-13-acétate de phorbol/effets indésirables , Animaux , Antioxydants , Marqueurs biologiques , Lignée de cellules transformées , Malformations , Développement embryonnaire/génétique , Épiderme , Humains , Inflammation/étiologie , Inflammation/métabolisme , Kératinocytes/métabolisme , Peroxydation lipidique , Oignons/effets des médicaments et des substances chimiques , Oignons/génétique , Oignons/métabolisme , Stress oxydatif , Espèces réactives de l'oxygène/métabolisme , Danio zébré
8.
Nutrients ; 12(6)2020 Jun 06.
Article de Anglais | MEDLINE | ID: mdl-32517205

RÉSUMÉ

Sea cucumber body wall contains several naturally occurring bioactive components that possess health-promoting properties. Isostichopus badionotus from Yucatan, Mexico is heavily fished, but little is known about its bioactive constituents. We previously established that I. badionotus meal had potent anti-inflammatory properties in vivo. We have now screened some of its constituents for anti-inflammatory activity in vitro. Glycosaminoglycan and soluble protein preparations reduced 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammatory responses in HaCaT cells while an ethanol extract had a limited effect. The primary glycosaminoglycan (fucosylated chondroitin sulfate; FCS) was purified and tested for anti-inflammatory activity in vivo. FCS modulated the expression of critical genes, including NF-ĸB, TNFα, iNOS, and COX-2, and attenuated inflammation and tissue damage caused by TPA in a mouse ear inflammation model. It also mitigated colonic colitis caused in mice by dextran sodium sulfate. FCS from I. badionotus of the Yucatan Peninsula thus had strong anti-inflammatory properties in vivo.


Sujet(s)
Anti-inflammatoires , Chondroïtines sulfate/isolement et purification , Chondroïtines sulfate/pharmacologie , Glycosaminoglycanes/isolement et purification , Glycosaminoglycanes/pharmacologie , Otite/traitement médicamenteux , Concombres de mer/composition chimique , Extraits tissulaires/isolement et purification , Extraits tissulaires/pharmacologie , Animaux , Chondroïtines sulfate/usage thérapeutique , Colite/induit chimiquement , Colite/traitement médicamenteux , Sulfate dextran/effets indésirables , Modèles animaux de maladie humaine , Cellules HaCaT , Humains , Techniques in vitro , Mexique , Souris , Otite/induit chimiquement , 12-Myristate-13-acétate de phorbol/effets indésirables
9.
Mycoses ; 63(2): 189-196, 2020 Feb.
Article de Anglais | MEDLINE | ID: mdl-31724251

RÉSUMÉ

BACKGROUND: Lanoconazole (LCZ) is a topical antifungal agent clinically used to treat fungal infections such as tinea pedis. LCZ has not only antifungal effects but also anti-inflammatory effects, which have the potential to provide additional clinical benefits. However, the characteristic features of the inhibitory effects of LCZ on skin inflammation remain unclear. OBJECTIVE: We evaluated the inhibitory effects of topical application of LCZ, and compared the effects of LCZ with those of other antifungal agents including liranaftate, terbinafine and amorolfine. METHODS: Each antifungal agent was topically applied on 12-O-tetradecanoylphorbol-13-acetate-induced irritant dermatitis and 2,4,6-trinitrophenyl chloride-induced contact dermatitis in mice (BALB/c). The ear thickness, myeloperoxidase activity and inflammatory mediator contents were evaluated. RESULTS: LCZ dose-dependently suppressed 12-O-tetradecanoylphorbol-13-acetate-induced irritant dermatitis, suppressed the production of neutrophil chemotactic factors such as keratinocyte-derived chemokine and macrophage inflammatory protein-2, and inhibited neutrophil infiltration to the inflammation site. Moreover, 1% LCZ reduced the ear swelling in mice with 2,4,6-trinitrophenyl chloride-induced contact dermatitis in accordance with the inhibition of interferon-γ production. The inhibitory potency of LCZ on these types of dermatitis in mice was stronger than that of other types of antifungal agents. CONCLUSION: The anti-inflammatory effects of LCZ were exerted through the inhibition of inflammatory mediator production. These effects may contribute to the relief of dermatitis symptoms in patients with tinea pedis.


Sujet(s)
Anti-inflammatoires non stéroïdiens/usage thérapeutique , Eczéma de contact/traitement médicamenteux , Imidazoles/usage thérapeutique , Picrates/effets indésirables , 12-Myristate-13-acétate de phorbol/effets indésirables , Pied d'athlète/anatomopathologie , Animaux , Antifongiques/usage thérapeutique , Eczéma de contact/étiologie , Eczéma de contact/prévention et contrôle , Relation dose-effet des médicaments , Oreille externe/effets des médicaments et des substances chimiques , Oreille externe/anatomopathologie , Femelle , Souris , Souris de lignée BALB C , Pied d'athlète/complications
10.
Sci Rep ; 9(1): 16760, 2019 11 14.
Article de Anglais | MEDLINE | ID: mdl-31728037

RÉSUMÉ

The human L-type amino acid transporter 1 (LAT1), also known as SLC7A5, catalyzes the transport of large neutral amino acids across the plasma membrane. As the main transporter of several essential amino acids, notably leucine, LAT1 plays an important role in mTORC1 activation. Furthermore, it is overexpressed in various types of cancer cells, where it contributes importantly to sustained growth. Despite the importance of LAT1 in normal and tumor cells, little is known about the mechanisms that might control its activity, for example by promoting its downregulation via endocytosis. Here we report that in HeLa cells, activation of protein kinase C by phorbol 12-myristate 13-acetate (PMA) triggers efficient endocytosis and degradation of LAT1. Under these conditions we found LAT1 downregulation to correlate with increased LAT1 ubiquitylation. This modification was considerably reduced in cells depleted of the Nedd4-2 ubiquitin ligase. By systematically mutagenizing the residues of the LAT1 cytosolic tails, we identified a group of three close lysines (K19, K25, K30) in the N-terminal tail that are important for PMA-induced ubiquitylation and downregulation. Our study thus unravels a mechanism of induced endocytosis of LAT1 elicited by Nedd4-2-mediated ubiquitylation of the transporter's N-terminal tail.


Sujet(s)
Transporteur-1 d'acides aminés neutres à longue chaîne/métabolisme , Mutation , Ubiquitine protéine ligases NEDD4/génétique , 12-Myristate-13-acétate de phorbol/effets indésirables , Sites de fixation , Régulation négative , Endocytose/effets des médicaments et des substances chimiques , Délétion de gène , Régulation de l'expression des gènes tumoraux/effets des médicaments et des substances chimiques , Cellules HeLa , Humains , Transporteur-1 d'acides aminés neutres à longue chaîne/composition chimique , Transporteur-1 d'acides aminés neutres à longue chaîne/génétique , Ubiquitination
11.
Mol Carcinog ; 58(2): 185-195, 2019 02.
Article de Anglais | MEDLINE | ID: mdl-30346064

RÉSUMÉ

Prevention remains an important strategy to reduce the burden of cancer. One approach to prevent cancer is the use of phytochemicals in various combinations as safe and effective cancer preventative agents. The purpose of this study was to examine the effects of the combination of ursolic acid (UA) and curcumin (Curc) for potential combinatorial inhibition of skin tumor promotion using the mouse two-stage skin carcinogenesis model. In short-term experiments, the combination of UA + Curc given topically prior to 12-O-tetradecanoylphorbol-13-acetate (TPA) significantly inhibited activation of epidermal EGFR, p70S6K, NF-κB p50, Src, c-Jun, Rb, and IκBα. Levels of c-Fos, c-Jun, and Cox-2 were also significantly reduced by the combination compared to the TPA treated group. The alterations in these signaling pathways by the combination of UA + Curc were associated with decreased epidermal proliferation as assessed by measuring BrdU incorporation. Significant effects were also seen with the combination on epidermal inflammatory gene expression and dermal inflammation, with the greatest effects on expression of IL-1ß, IL-6, IL-22, and CXCL2. Furthermore, results from skin tumor experiments demonstrated that the combination of UA + Curc given topically significantly inhibited mouse skin tumor promotion by TPA to a greater extent than the individual compounds given alone. The greatest effects were seen on tumor free survival, tumor size, and tumor weight, although tumor incidence and multiplicity were also further reduced by the combination. These results demonstrate the potential cancer chemopreventive activity and mechanism(s) for the combination of UA + Curc.


Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/administration et posologie , Curcumine/administration et posologie , Tumeurs cutanées/traitement médicamenteux , 12-Myristate-13-acétate de phorbol/effets indésirables , Triterpènes/administration et posologie , Administration par voie topique , Animaux , Protocoles de polychimiothérapie antinéoplasique/pharmacologie , Chimiokine CXCL2/génétique , Chimiokine CXCL2/métabolisme , Curcumine/pharmacologie , Femelle , Régulation de l'expression des gènes tumoraux/effets des médicaments et des substances chimiques , Interleukine-1 bêta/génétique , Interleukine-1 bêta/métabolisme , Interleukine-6/génétique , Interleukine-6/métabolisme , Interleukines/génétique , Interleukines/métabolisme , Souris , Transduction du signal/effets des médicaments et des substances chimiques , Tumeurs cutanées/induit chimiquement , Tumeurs cutanées/génétique , Tumeurs cutanées/métabolisme , Résultat thérapeutique , Triterpènes/pharmacologie , Tests d'activité antitumorale sur modèle de xénogreffe , ,
12.
Molecules ; 23(12)2018 Dec 10.
Article de Anglais | MEDLINE | ID: mdl-30544700

RÉSUMÉ

As a folk medicine, Moringa oleifera L. is used effectively to treat inflammatory conditions and skin diseases. However, its mechanism of action is not well understood, limiting its medical use. We isolated and identified three compounds, namely niazirin, marumoside A and sitosterol-3-O-ß-d-glucoside, from the seeds of Moringa oleifera, and studied their effects on the expression of Th17-relevant cytokines (IL-12/IL-23 p40, IL-17A, IL-22 and IL-23 p19) using lipopolysaccharide-stimulated THP-1 cells. Additionally, as Th17 plays a critical role in the pathogenesis of psoriasis, we used a 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced psoriasis-like skin lesion mouse model to study their potential therapeutic application in vivo. The compounds suppressed the expression of IL-12/IL-23 p40, IL-17A, IL-22 and IL-23 p19 in vitro, and in vivo they ameliorated psoriasis-like skin lesions, decreased IL-17A mRNA expression, and increased the expression of keratinocyte differentiation markers. To our knowledge, this is the first report regarding the mechanism and therapeutic application of Moringa oleifera seeds to treat psoriasis-like lesions in vivo.


Sujet(s)
Cytokines/génétique , Moringa oleifera/composition chimique , Extraits de plantes/administration et posologie , Psoriasis/traitement médicamenteux , 12-Myristate-13-acétate de phorbol/effets indésirables , Cellules Th17/immunologie , Animaux , Modèles animaux de maladie humaine , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Hétérosides/administration et posologie , Hétérosides/isolement et purification , Hétérosides/pharmacologie , Humains , Lipopolysaccharides/effets indésirables , Souris , Structure moléculaire , Extraits de plantes/composition chimique , Extraits de plantes/pharmacologie , Psoriasis/induit chimiquement , Psoriasis/génétique , Pyrroles/administration et posologie , Pyrroles/isolement et purification , Pyrroles/pharmacologie , Graines/composition chimique , Sitostérol/administration et posologie , Sitostérol/isolement et purification , Sitostérol/pharmacologie , Cellules Th17/effets des médicaments et des substances chimiques
13.
J Pharmacol Exp Ther ; 366(1): 1-8, 2018 07.
Article de Anglais | MEDLINE | ID: mdl-29695409

RÉSUMÉ

We have previously shown that phosphatidylglycerol (PG) regulates the function of keratinocytes, the predominant cells that compose the epidermis, inhibiting the proliferation of rapidly dividing keratinocytes. In particular, soy PG, a PG mixture with a high proportion of polyunsaturated fatty acids, is efficacious at inhibiting these proliferating keratinocytes. Psoriasis is a skin disorder characterized by hyperproliferation of keratinocytes and inflammation. Data in the lung suggest that PG in pulmonary surfactant inhibits inflammation. To investigate the possibility of using PG containing polyunsaturated fatty acids for the treatment of psoriasis, we examined the effect of soy PG on inflammation induced by the application of 12-O-tetradecanoylphorbol 13-acetate (TPA), a contact irritant, to mouse ears in vivo. We monitored ear thickness and weight as a measure of ear edema, as well as CD45-positive immune cell infiltration. Our results indicate that soy PG when applied together with 1,25-dihydroxyvitamin D3 (vitamin D), an agent known to acutely disrupt the skin barrier, suppressed ear edema and inhibited the infiltration of CD45-positive immune cells. On the other hand, neither PG nor vitamin D alone was effective. The combination also decreased tumor necrosis factor-α (TNFα) levels. This result suggested the possibility that PG was not permeating the skin barrier efficiently. Therefore, in a further study we applied PG in a penetration-enhancing vehicle and found that it inhibited inflammation induced by the phorbol ester and decreased CD45-positive immune cell infiltration. Our results suggest the possibility of using soy PG as a topical treatment option for psoriasis.


Sujet(s)
Oedème/induit chimiquement , Oedème/traitement médicamenteux , Glycine max/composition chimique , Irritants/effets indésirables , Phosphatidylglycérol/pharmacologie , Animaux , Modèles animaux de maladie humaine , Oedème/immunologie , Oedème/anatomopathologie , Inflammation/traitement médicamenteux , Kératinocytes/effets des médicaments et des substances chimiques , Mâle , Souris , Phosphatidylglycérol/usage thérapeutique , 12-Myristate-13-acétate de phorbol/effets indésirables
14.
Oncol Rep ; 39(6): 2513-2526, 2018 Jun.
Article de Anglais | MEDLINE | ID: mdl-29693192

RÉSUMÉ

Salidroside (SR) is a main component of Rhodiola rosea L. and exhibits a variety of pharmacologic properties. The present study was carried out to explore the potential effect of SR against skin cancer induced by 7,12-dimethylbenz(a)anthracene (DMBA) and 12-O-tetradecanoylphorbol-13­acetate (TPA) in female Institute for Cancer Research (ICR) mice and to reveal the underlying molecular targets regulated by SR. The mice were randomly divided into 4 groups: control, DMBA/TPA, DMBA/TPA+SR (20 mg/kg) and DMBA/TPA+SR (40 mg/kg). SR was administered to mice five times a week after DMBA treatments. In our study, we found that SR dose-dependently ameliorated skin cancer incidence and the multiplicity in the animal models by reducing the release of inflammation-related cytokines, including tumor necrosis factor α (TNF-α), interleukin-1ß (IL-1ß), interleukin-18 (IL-18), interleukin-6 (IL-6), cyclooxygenase 2 (COX2) and transforming growth factor ß-1 (TGF-ß1). Suppression of the nuclear factor (NF)-κB signaling pathway by SR was effective to prevent skin carcinogenesis. Furthermore, TUNEL analysis indicated that compared to the DMBA/TPA group, enhanced apoptosis was observed in the DMBA/TPA+SR group. In addition, p53 expression levels were increased by SR in the DMBA/TPA-induced mice. Therefore, SR was effective for inducing apoptosis during skin cancer progression triggered by DMBA/TPA. Consistently, p21, p53 upregulated modulator of apoptosis (PUMA), Bax and caspase-3 were highly induced by SR to enhance the apoptotic response for preventing skin cancer. Moreover, in vitro, we found that SR dramatically reduced the inflammatory response, while enhancing the aoptotic response by blocking NF-κB and activating caspase-3 pathways, respectively. In addition, flow cytometric analysis further confirmed the induction of apoptosis by SR in DMBA-treated cells in vitro. Taken together, the in vivo and in vitro studies illustrated that SR might be a promising compound to reduce skin cancer risk.


Sujet(s)
7,12-Diméthyl-benzo[a]anthracène/effets indésirables , Anti-inflammatoires non stéroïdiens/administration et posologie , Antinéoplasiques d'origine végétale/administration et posologie , Glucosides/administration et posologie , Phénols/administration et posologie , Tumeurs cutanées/prévention et contrôle , 12-Myristate-13-acétate de phorbol/effets indésirables , Animaux , Anti-inflammatoires non stéroïdiens/pharmacologie , Antinéoplasiques d'origine végétale/pharmacologie , Apoptose , Lignée cellulaire tumorale , Survie cellulaire/effets des médicaments et des substances chimiques , Cytokines/métabolisme , Calendrier d'administration des médicaments , Régulation de l'expression des gènes tumoraux/effets des médicaments et des substances chimiques , Glucosides/pharmacologie , Humains , Souris , Phénols/pharmacologie , Répartition aléatoire , Tumeurs cutanées/induit chimiquement , Tumeurs cutanées/immunologie , Protéine p53 suppresseur de tumeur/génétique , Tests d'activité antitumorale sur modèle de xénogreffe
15.
Mol Med Rep ; 17(1): 630-635, 2018 Jan.
Article de Anglais | MEDLINE | ID: mdl-29115448

RÉSUMÉ

Inflammation­associated damage may occur in any tissue following infection, exposure to toxins, following ischemia, and in allergic and auto­immune reactions. Inflammation may also result from mast cell degranulation induced by the intracellular calcium concentration. The inflammatory process may be inhibited by compounds that affect mast cells. Bisdemethoxycurcumin [1,7­bis(4­hydroxyphenyl) hepta­1,6­diene­3,5­dione, BDCM] is the active component of turmeric. It has anticancer, antioxidant and antibacterial properties. To investigate the molecular mechanism associated with the anti­inflammatory activity of BDCM, human mast cell line 1 (HMC­1) cells were treated with phorbol­12­myristate­13­acetate (PMA) and calcium ionophore A23187 (A23187) to induce the inflammatory process. Various HMC­1 cells were pretreated with BDCM prior to stimulation of inflammation. BDCM inhibited the inflammation­triggered production of cytokines including interleukin (IL)­6, IL­8, and tumor necrosis factor (TNF)­α. BDCM inhibition extended to the gene level. In activated HMC­1 cells, phosphorylation levels of extracellular signal­regulated kinase, c­jun N­terminal kinase and p38 mitogen­activated protein kinase were decreased by treatment with BDCM. BDCM also inhibited nuclear factor­(NF)­κB activation and IκB degradation. In conclusion, BDCM suppresses the expression of TNF­α, IL­8, and IL­6 by inhibiting the NF­κB and mitogen activated protein kinase signaling pathways.


Sujet(s)
Curcumine/analogues et dérivés , Inflammation/traitement médicamenteux , Facteur de transcription NF-kappa B/génétique , A-23187/effets indésirables , Lignée cellulaire , Curcumine/administration et posologie , Diarylheptanoïdes , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Humains , Inflammation/induit chimiquement , Inflammation/génétique , Inflammation/anatomopathologie , Mastocytes/métabolisme , Mastocytes/anatomopathologie , Mitogen-Activated Protein Kinase Kinases/génétique , Transduction du signal/effets des médicaments et des substances chimiques , 12-Myristate-13-acétate de phorbol/effets indésirables , 12-Myristate-13-acétate de phorbol/analogues et dérivés , Facteur de transcription RelA/génétique
16.
Mol Med Rep ; 17(1): 1077-1082, 2018 Jan.
Article de Anglais | MEDLINE | ID: mdl-29115558

RÉSUMÉ

The present study was designed to investigate the tumor inhibitory potential of bryostatin 1 in a 12­O­tetradecanoylphorbol­13­acetate (TPA)­induced mouse model of skin cancer. The radical inhibition potential of various doses of bryostatin 1 was investigated against 2,2­diphenyl­1­picrylhydrazyl (DPPH) bleach in vitro. The DPPH radical potential was observed compared with treatment with 5, 10, 15, 20, 25 and 30 µM doses of bryostatin 1. In vivo, bryostatin 1 prevented the TPA­mediated increase in the level of H2O2 and myeloperoxidase in mouse epidermal tissue. Pretreatment of the mice with bryostatin 1 (30 µM) followed by administration of TPA reduced the edema, as demonstrated via punched­out mouse ear tissue, to 7.2 mg, compared with 14 mg in the TPA­treated group. Treatment with bryostatin 1 prior to TPA administration markedly prevented the inflammation of the skin by inhibiting hyperplasia in the epidermal layer and the aggregation of inflammatory cells. The results demonstrated that treatment of mice with bryostatin 1 at a 30 µM dose prior to TPA administration significantly (P<0.005) inhibited the TPA­mediated increase in the level of COX­2. The activity of ornithine decarboxylase, increased by TPA, was additionally inhibited following pretreatment of the mice with bryostatin 1. In the mice treated with bryostatin 1 at 30 µM doses prior to the administration of TPA, the appearance of papillomas was 20%, compared with 100% in the TPA group. Mice pretreated with bryostatin 1 at 30 µM doses prior to TPA administration exhibited the appearance of 0.4 mean papillomas in each animal, compared with 5.2 in the TPA group. Therefore, the results of the present study demonstrated that bryostatin 1 inhibited the development and progression of tumors of skin in the mice, through the prevention of inflammation­inducing processes and the quenching of radicals. Therefore, bryostatin 1 maybe considered to be adrug of importance in the treatment of skin tumor.


Sujet(s)
Antinéoplasiques/pharmacologie , Bryostatines/pharmacologie , Tumeurs cutanées/induit chimiquement , Tumeurs cutanées/anatomopathologie , 12-Myristate-13-acétate de phorbol/effets indésirables , Animaux , Antinéoplasiques/composition chimique , Bryostatines/composition chimique , Cyclooxygenase 2/métabolisme , Modèles animaux de maladie humaine , Oedème/anatomopathologie , Femelle , Souris , Ornithine decarboxylase/métabolisme , Myeloperoxidase/métabolisme , Tumeurs cutanées/traitement médicamenteux , Tumeurs cutanées/métabolisme
17.
J Cell Biochem ; 117(12): 2769-2780, 2016 12.
Article de Anglais | MEDLINE | ID: mdl-27138049

RÉSUMÉ

Toad skin extracts, such as aqueous extracts (AE) of Chinese toad skins, have demonstrated therapeutic benefits for a range of diseases including pain, inflammation, swelling, heart failure, and various types of cancers. In this study, we investigated the anti-inflammatory potential of an AE (0.1-10 µg/mL) and a 60% ethanol extract (EE; 0.1-10 µg/mL) from Australian cane toad (Bufo marinus) skins and the known bioactive compound, bufotenine (BT; 0.1-10 nM). The assay employed a model of the human monocyte cell line U937 stimulated with lipopolysaccharide (LPS) and phorbol 12-myristate 13-acetate (PMA) for the release of tumor necrosis factor (TNF)-α and interleukin (IL)-6. We demonstrated that AE, EE, and BT significantly inhibited the release and expression of TNF-α and IL-6 in a dose-dependent manner when the cells were pre-treated at non-cytotoxic concentrations. Further investigation revealed that the inhibition of TNF-α and IL-6 release and expression was associated with the suppression of nuclear factor (NF)-kappa (κ)B activation. These results indicate that AE, EE, and BT are strong inflammation inhibitors, thus have the potential for further development as anti-inflammatory therapeutic agents from a natural source regarded as a feral pest in Australia. J. Cell. Biochem. 117: 2769-2780, 2016. © 2016 Wiley Periodicals, Inc.


Sujet(s)
Produits biologiques/pharmacologie , Bufanolide/pharmacologie , Cytokines/métabolisme , Éthanol/composition chimique , Inflammation/prévention et contrôle , Monocytes/métabolisme , Facteur de transcription NF-kappa B/métabolisme , Animaux , Anti-inflammatoires/pharmacologie , Anura , Apoptose/effets des médicaments et des substances chimiques , Technique de Western , Cardiotoniques/pharmacologie , Prolifération cellulaire/effets des médicaments et des substances chimiques , Cytokines/génétique , Technique d'immunofluorescence , Humains , Inflammation/induit chimiquement , Inflammation/métabolisme , Interleukine-6/génétique , Interleukine-6/métabolisme , Lipopolysaccharides/effets indésirables , Monocytes/cytologie , Monocytes/effets des médicaments et des substances chimiques , Facteur de transcription NF-kappa B/génétique , ARN messager/génétique , Réaction de polymérisation en chaine en temps réel , RT-PCR , Transduction du signal/effets des médicaments et des substances chimiques , Peau/composition chimique , 12-Myristate-13-acétate de phorbol/effets indésirables , Facteur de nécrose tumorale alpha/génétique , Facteur de nécrose tumorale alpha/métabolisme
18.
BMC Complement Altern Med ; 15(1): 431, 2015 Dec 05.
Article de Anglais | MEDLINE | ID: mdl-26638207

RÉSUMÉ

BACKGROUND: Drastic increment of skin cancer incidence has driven natural product-based chemoprevention as a promising approach in anticancer drug development. Apart from its traditional usages against various ailments, Ardisia crispa (Family: Myrsinaceae) specifically its triterpene-quinone fraction (TQF) which was isolated from the root hexane extract (ACRH) was recently reported to exert antitumor promoting activity in vitro. This study aimed at determining chemopreventive effect of TQF against chemically-induced mouse skin tumorigenesis as well as elucidating its possible pathway(s). METHODS: Mice (n = 10) were initiated with single dose of 7,12-dimethylbenz[α]anthracene (DMBA) (390 nmol/100 µl) followed by, a week later, repeated promotion (twice weekly; 20 weeks) with 12-O-tetradecanoylphorbol-13-acetate (TPA) (1.7 nmol/100 µl). TQF (10, 30 and 100 mg/kg) and curcumin (10 mg/kg; reference) were, respectively, applied topically to DMBA/TPA-induced mice 30 min before each TPA application. Upon termination, histopathological and biochemical analysis, as well as Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and transcription factor enzyme-linked immunosorbent assay (ELISA) assays were performed to elucidate the potential mechanism of TQF. RESULTS: With comparison to the carcinogen control, results revealed that lower dose of TQF (10 mg/kg) conferred antitumor promoting effect via significant (P < 0.05) suppression against lipid peroxidation (LPO), apoptotic index (cell death) and nuclear factor-kappa B (NF-κB), along with reduction of keratinocyte proliferation; whilst its higher dose (100 mg/kg) was found to promote tumorigenesis by significantly (P < 0.05) increasing LPO and apoptotic index, in addition to aggravating keratinocyte proliferation. CONCLUSIONS: This study evidenced that TQF, particularly at its lower dosage (10 mg/kg), ameliorated DMBA/TPA-induced mouse skin tumorigenesis. Though, future investigations are warranted to determine the lowest possible therapeutic dose of TQF in subsequent in vivo chemopreventive studies.


Sujet(s)
Anticarcinogènes/administration et posologie , Ardisia , Quinones/administration et posologie , Tumeurs cutanées/prévention et contrôle , Peau/effets des médicaments et des substances chimiques , Triterpènes/administration et posologie , 7,12-Diméthyl-benzo[a]anthracène/effets indésirables , Administration par voie topique , Animaux , Transformation cellulaire néoplasique/effets des médicaments et des substances chimiques , Fractionnement chimique , Chimioprévention , Curcumine/administration et posologie , Modèles animaux de maladie humaine , Test ELISA , Mâle , Souris , Souris de lignée ICR , Extraits de plantes/administration et posologie , Racines de plante , Peau/anatomopathologie , Tumeurs cutanées/induit chimiquement , 12-Myristate-13-acétate de phorbol/effets indésirables
19.
PLoS One ; 10(8): e0135840, 2015.
Article de Anglais | MEDLINE | ID: mdl-26284516

RÉSUMÉ

PURPOSE: The aim of this study was to evaluate the antiproliferative activity in breast cancer cells and the inhibition of tumorigenesis in pre-neoplastic cells of a new apple cultivar with reddish pulp, called the Pelingo apple. METHODS: The antiproliferative activity was evaluated in MCF-7 and MDA-MB-231 human breast cancer cells. The inhibition of tumorigenesis was performed in JB6 promotion-sensitive (P+) cells. RESULTS: Results showed that Pelingo apple juice is characterized by a very high polyphenol content and strongly inhibited breast cancer cell proliferation. Its antiproliferative activity was found to be higher than the other five apple juices tested. Pelingo juice induced cell accumulation in the G2/M phase of the cell cycle and autophagy through overexpression of p21, inhibition of extracellular signal-regulated kinases 1/2 (ERK1/2) activity and an increase in lipidated microtubule-associated protein-1 light chain-3 beta (LC3B). Remarkably, Pelingo juice inhibited the 12-o-tetra-decanoyl-phorbol-13-acetate (TPA)-induced tumorigenesis of JB6 P+ cells, suppressing colony formation in semi-solid medium and TPA-induced ERK1/2 phosphorylation. CONCLUSIONS: Our data indicate that the Pelingo apple is rich in food components that can markedly inhibit in vitro tumorigenesis and growth of human breast cancer cells and could provide natural bioactive non-nutrient compounds, with potential chemopreventive activity.


Sujet(s)
Antinéoplasiques/pharmacologie , Tumeurs du sein/anatomopathologie , Carcinogenèse/effets des médicaments et des substances chimiques , Jus de fruits et de légumes/analyse , Malus/composition chimique , Anthocyanes/analyse , Antinéoplasiques/composition chimique , Carcinogenèse/induit chimiquement , Division cellulaire/effets des médicaments et des substances chimiques , Prolifération cellulaire/effets des médicaments et des substances chimiques , Inhibiteur p21 de kinase cycline-dépendante/métabolisme , Phase G2/effets des médicaments et des substances chimiques , Humains , Cellules MCF-7 , Protéines associées aux microtubules/métabolisme , Mitogen-Activated Protein Kinase 1/antagonistes et inhibiteurs , Mitogen-Activated Protein Kinase 3/antagonistes et inhibiteurs , Polyphénols/analyse , 12-Myristate-13-acétate de phorbol/effets indésirables
20.
Food Chem Toxicol ; 81: 1-8, 2015 Jul.
Article de Anglais | MEDLINE | ID: mdl-25846502

RÉSUMÉ

Epidemiologic and animal studies revealed that capsaicin (8-methyl-N-vanillyl-6-noneamide) can act as a carcinogen or cocarcinogen. However, the influence of consumption of capsaicin-containing foods or vegetables on skin cancer patients remains largely unknown. In the present study, we demonstrated that capsaicin has a cocarcinogenic effect on 9, 10-dimethylbenz[a]anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin tumorigenesis. Our results showed that topical application of capsaicin on the dorsal skin of DMBA-initiated and TPA-promoted mice could significantly accelerate tumor formation and growth and induce more and larger skin tumors than the model group (DMBA + TPA). Moreover, capsaicin could promote TPA-induced skin hyperplasia and tumor proliferation. Mechanistic study found that inflammation-related factors cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) were highly elevated by pretreatment with capsaicin, suggesting an inflammation-dependent mechanism. Furthermore, mice that were administered capsaicin exhibited significant up-regulation of phosphorylation of nuclear factor kappaB (NF-κB), Erk and p38 but had no effect on JNK. Thus, our results indicated that inflammation, Erk and P38 collectively played a crucial role in cancer-promoting effect of capsaicin on carcinogen-induced skin cancer in mice.


Sujet(s)
7,12-Diméthyl-benzo[a]anthracène/effets indésirables , Capsaïcine/effets indésirables , Système de signalisation des MAP kinases , Tumeurs cutanées/induit chimiquement , 12-Myristate-13-acétate de phorbol/effets indésirables , p38 Mitogen-Activated Protein Kinases/métabolisme , Animaux , Carcinogenèse/anatomopathologie , Cyclooxygenase 2/génétique , Cyclooxygenase 2/métabolisme , Femelle , Hyperplasie/induit chimiquement , Hyperplasie/anatomopathologie , Inflammation/induit chimiquement , Inflammation/anatomopathologie , JNK Mitogen-Activated Protein Kinases/génétique , JNK Mitogen-Activated Protein Kinases/métabolisme , Souris , Souris de lignée ICR , Facteur de transcription NF-kappa B/génétique , Facteur de transcription NF-kappa B/métabolisme , Nitric oxide synthase type II/génétique , Nitric oxide synthase type II/métabolisme , Phosphorylation , Peau/effets des médicaments et des substances chimiques , Régulation positive , p38 Mitogen-Activated Protein Kinases/génétique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...